NCT06686394 - Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

September 10, 2029

Study Completion Date

September 10, 2029

Conditions

Breast NeoplasmsBreast Cancer

Interventions

BIOLOGICAL

Patritumab deruxtecan

Patritumab deruxtecan administered via IV infusion

BIOLOGICAL

Trastuzumab

Trastuzumab administered via IV infusion

BIOLOGICAL

Trastuzumab Biosimilar

Trastuzumab biosimilar administered via IV infusion

BIOLOGICAL

Pertuzumab

Pertuzumab administered via IV infusion

BIOLOGICAL

Tucatinib

Tucatinib administered as oral tablets

Trial Locations (14)

22031

RECRUITING

Inova Schar Cancer Institute ( Site 0051), Fairfax

29605

RECRUITING

Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville

3109601

RECRUITING

Rambam Health Care Campus ( Site 0011), Haifa

4941492

RECRUITING

Rabin Medical Center ( Site 0012), Petah Tikva

5265601

RECRUITING

Sheba Medical Center ( Site 0010), Ramat Gan

02215

RECRUITING

Dana-Farber Cancer Institute ( Site 0050), Boston

08901

RECRUITING

Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre ( Site 0001), Toronto

H3T 1E2

RECRUITING

Jewish General Hospital ( Site 0003), Montreal

467-8602

RECRUITING

Nagoya City University Hospital ( Site 0020), Nagoya

03080

RECRUITING

Seoul National University Hospital ( Site 0030), Seoul

05505

RECRUITING

Asan Medical Center ( Site 0031), Seoul

NW1 2PG

RECRUITING

University College London Hospital ( Site 0041), London

EC1A 7BE

RECRUITING

St Bartholomew s Hospital ( Site 0040), London